SCHEMBL24559156

SCHEMBL24559156

Cn1c(=S)c2c(ncn2Cc2ccc(C=C3C(=O)NC(=O)NC3=O)cc2)n(C)c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ ABCC8 Q09428 1/20 0.47
▸ KCNJ11 Q14654 1/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ ADORA2B P29275 3/20 0.47
▸ RXFP1 Q9HBX9 2/20 0.47
▸ HTT P42858 2/20 0.46
▸ UBE2N P61088 2/20 0.46
▸ GLA P06280 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ POLB P06746 1/20 0.41
▸ HIF1A Q16665 1/20 0.41
▸ TP53 P04637 1/20 0.39
▸ MAPT P10636 2/20 0.38
▸ PPARG P37231 1/20 0.38
▸ METAP1 P53582 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24559268 0.90 LMNA (0.63) LMNAMAPK1ABCC8KCNJ11SMN1; SMN2
SCHEMBL24559245 0.86 LMNA (0.60) LMNAMAPK1ABCC8KCNJ11SMN1; SMN2
SCHEMBL24559153 0.85 LMNA (0.51) LMNAMAPK1ABCC8KCNJ11SMN1; SMN2
SCHEMBL24559151 0.85 LMNA (0.48) LMNAMAPK1ABCC8KCNJ11SMN1; SMN2
SCHEMBL24666144 0.84 LMNA (0.46) LMNAMAPK1ABCC8KCNJ11SMN1; SMN2
SCHEMBL24666143 0.84 LMNA (0.58) LMNAMAPK1ABCC8KCNJ11SMN1; SMN2
SCHEMBL24559279 0.83 MYC (0.52) LMNAMAPK1ABCC8KCNJ11SMN1; SMN2
SCHEMBL24559307 0.80 LMNA (0.61) LMNAMAPK1ABCC8KCNJ11SMN1; SMN2
SCHEMBL24559129 0.78 LMNA (0.60) LMNAMAPK1ABCC8KCNJ11SMN1; SMN2
SCHEMBL22521806 0.78 SMN1; SMN2 (0.76) LMNAMAPK1ABCC8KCNJ11SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109892-A1 POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) INHIBITORS AGAINST COVID MACRODOMAIN AND METHODS OF USING THE SAME NATIONAL INSTITUTES OF HEALTH 2024-04-04 — — US disclosed
WO-2022159818-A1 POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) INHIBITORS AGAINST COVID MACRODOMAIN AND METHODS OF USING THE SAME BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-07-28 — — WO disclosed
WO-2022159818-A1 POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) INHIBITORS AGAINST COVID MACRODOMAIN AND METHODS OF USING THE SAME BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-07-28 — — WO disclosed
US-20220202821-A1 SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-06-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109892-A1 POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) INHIBITORS AGAINST COVID MACRODOMAIN AND METHODS OF USING THE SAME MACROD2, MACROD1, PARG LMNA 1439/4885MAPK1 3974/4885ABCC8 2082/4885
US-20220202821-A1 SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF PARG, PARP15, PLG LMNA 854/4885MAPK1 2790/4885ABCC8 3861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback